Coordinated Financial Services Inc. Makes New $629,000 Investment in Stryker Co. (NYSE:SYK)

Coordinated Financial Services Inc. bought a new stake in Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,748 shares of the medical technology company's stock, valued at approximately $629,000.

Other large investors have also recently bought and sold shares of the company. Chicago Capital LLC raised its position in Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock valued at $70,228,000 after purchasing an additional 5,841 shares during the last quarter. Zhang Financial LLC increased its stake in shares of Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock valued at $41,366,000 after buying an additional 40,784 shares during the period. Appleton Partners Inc. MA increased its stake in shares of Stryker by 5.0% in the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after buying an additional 1,400 shares during the period. Metis Global Partners LLC increased its stake in shares of Stryker by 10.2% in the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock valued at $6,064,000 after buying an additional 1,561 shares during the period. Finally, US Bancorp DE increased its stake in shares of Stryker by 0.5% in the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock valued at $65,829,000 after buying an additional 976 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Stock Down 0.8 %

Shares of SYK stock traded down $3.03 during trading hours on Friday, reaching $379.28. The company had a trading volume of 1,961,830 shares, compared to its average volume of 1,209,637. The company has a market cap of $144.73 billion, a price-to-earnings ratio of 48.88, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The business has a fifty day simple moving average of $382.45 and a 200-day simple moving average of $373.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm earned $3.46 EPS. On average, research analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.89%. Stryker's payout ratio is presently 43.30%.

Analyst Ratings Changes

Several brokerages have recently weighed in on SYK. Stifel Nicolaus increased their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. The Goldman Sachs Group increased their price target on Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a research note on Thursday, January 30th. StockNews.com cut Stryker from a "buy" rating to a "hold" rating in a research note on Thursday. Morgan Stanley raised Stryker from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research note on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and an average target price of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.